Navigation Links
Singapore clinician-scientists identify new type of deadly lymphoma
Date:4/1/2013

Singapore, 31 March 2013 An international research team has identified a new type of deadly intestinal lymphoma that is particularly common in Asia. The team, led by clinician-scientists from the SingHealth Academic Healthcare Cluster, also developed a new diagnostic test to accurately identify these patients.

The study, carried out by the Singapore Lymphoma Study Group at Singapore General Hospital (SGH) and the National Cancer Centre Singapore (NCCS), has an immediate impact on patient care, with doctors now able to diagnose patients accurately and tailor more effective treatment strategies to improve outcomes. It will also impact the most recent WHO classification of haematolymphoid neoplasms.

This is the largest study of this lymphoma type, involving 60 cases from centres in Singapore and around Asia, including South Korea, Hong Kong, Taiwan, Australia, China and Malaysia. The findings were advanced published online in Leukemia earlier this month.

The disease, almost unheard of before 2008, has been classified as an alternative type of enteropathy-associated T-cell lymphoma (EATL Type I), a disease common in Caucasians and associated with coeliac disease.

"We discovered that the intestinal lymphoma commonly seen in Asian patients has no links to coeliac disease or EATL Type I found in Caucasians," said Associate Professor Tan Soo Yong, Senior Consultant, Department of Pathology at SGH, and first author of the study. "Instead, we discovered that the pathology of this disease is very different and most likely originates from a unique epithelial cell type found in the intestine, making it a completely different disease type."

"We, therefore, propose to re-classify the disease, currently labelled EATL Type II, as 'Epitheliotropic Intestinal T-cell Lymphoma' (EITL)," added Assoc Prof Tan, who is also Director of the SingHealth Tissue Repository and a faculty at Duke-NUS. This would impact the WHO's classification.

In addition, the team has identified a novel biomarker, known as MATK (megakaryocyte-associated tyrosine kinase), and developed a diagnostic test that enables clinicians to accurately diagnose patients suffering from this type of lymphoma. Requests for this test have come in from around the world, including China and the U.S.

"Our research has an immediate impact on the care we can provide to patients with this rare but very aggressive intestinal lymphoma," said Associate Prof Lim Soon Thye, Deputy Head and Senior Consultant, Department of Medical Oncology, NCCS, and Associate Professor at Duke-NUS. "With an accurate diagnosis, we can treat our patients better and improve overall survival." The average overall survival observed by the researchers was only seven months.

The study is a testimony to the close collaboration between scientists, pathologists and clinicians in the Singapore Lymphoma Study Group and investigators from across the region. "It underscores the importance of working with a multidisciplinary team across institutions and countries to address gaps in research in Asia," added Assoc Prof Lim, who is the senior author of the study.

Expanding on the benefit of a multi-disciplinary approach, Professor Teh Bin Tean, Professor at NCCS and Duke-NUS, said: "One of the advantages of pursuing academic medicine is that we can approach questions seen at the bedside from all angles, avoiding a silo approach. And once we have results, the different team members bring this knowledge back to their different specialties to develop diagnostic kits, identify potential drug candidates or to implement changes to clinical practice."

Next, the researchers plan to collaborate with international experts in the United States and Canada to investigate the cell of origin and explore immunological approaches to block its growth.


'/>"/>

Contact: Lydia Ng
lydia.ng.w.r@singhealth.com.sg
659-271-6175
SingHealth
Source:Eurekalert

Related medicine news :

1. EP Global Communications, Inc, EPGL Medical Begins Selling MPDD Devices, Singapore Distributor Secures First 1,000 Units Off Assembly Line
2. Singapore scientists led by A*STARs GIS identify 4 mechanisms that contribute to gastric cancers
3. National Cancer Centre Singapore scientists discover p53 mutation hinders cancer treatment response
4. One Stop Skin Care Solutions for Dermatological Conditions in Singapore
5. Singapore scientists identify new biomarker for cancer in bone marrow
6. Regular Distributor Conference Calls Planned For Marketing Xocolate International
7. Xocai Mayalsia
8. Xocai Taiwan
9. Xocai Singapore
10. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Improves the My Diet Doc Health Questionnaire; Better Identifying Internal Factors that May Hinder Fast Weight Loss
11. Scientists identify brains molecular memory switch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... February 06, 2016 , ... With the FCPX LUT: Summer ... grades to their footage. A LUT is a Lookup Table that contains a mathematical ... color indicated by the table. By manipulating each pixel, LUT's can change each color ...
(Date:2/5/2016)... ... 05, 2016 , ... VeloReality President and co-founder ... LYNX VR Indoor Trainer with multi-rider capability to an enthusiastic audience at the ... reduce the weight of the unit, they also enhance the rider's experience with ...
(Date:2/5/2016)... Santa Rosa, CA (PRWEB) , ... February 05, ... ... are pleased to announce the addition of micro-needling services in their Napa Valley ... appearance. The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are ...
(Date:2/5/2016)... ... February 05, 2016 , ... US Sports Camps , official operators ... to direct high-performance kids yoga training. ChildLight Yoga Studio is centrally situated in the ... Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, “We are thrilled ...
(Date:2/5/2016)... ... February 05, 2016 , ... Boar’s Head Brand®, one of the nation’s ... weekend’s Big Game. Take the stress out of your party preparation – follow these ... at every stage of the game. , “The key to hosting a successful game-day ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 2016  Aralez Pharmaceuticals Inc. ("Aralez") today announced the ... Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval of the ... The combined company will operate under Aralez Pharmaceuticals Inc. ... Canada , Ireland ... Under the terms of the Agreement and Plan of ...
(Date:2/5/2016)... New York , February 5, 2016 ... new Transparency Market Research report states that the global ... in 2014 and is predicted to reach US$185.9 bn ... CAGR of 6.50% from 2014 to 2020. The title ... (Branded/Generic/Over-the-counter, Chemical/Biological, Captive/Contract Manufactured, by Geography, and by Therapeutic ...
(Date:2/5/2016)... -- Henry Schein, Inc. (NASDAQ: HSIC ), the world,s largest ... dental, animal health and medical practitioners, announced today that ... majority ownership interest in Dental Cremer S.A., a distributor ... . --> ... dental distribution business of Cremer S.A. With 2015 sales ...
Breaking Medicine Technology: